Table 6.

KQ3 UK NSC 2020 eligibility criteria (benefits and harms of treatment)

	Inclusion criteria	Exclusion criteria
Population	Individuals over 18 years with localized (early stage) prostate cancer	N/A
Interventions	Any of the following interventions: surgery, high-intensity focused ultrasonography, radiation therapy, ablative therapy, hormonotherapy	Any non-approved or experimental treatment
Comparator	No treatment, the same intervention with a minor difference (e.g., difference in dose or scheduling), watchful waiting, or active surveillance	Any other comparators
Outcomesa	Potential benefits 1. Reduced prostate cancer mortality 2. Reduced all-cause mortality 3. Decreased rate of metastasis development Potential harms 4. Incontinence (urinary or bowel) 5. Erectile dysfunction 6. Complications due to treatment (i.e., surgical AEs, radiotherapy toxicity, endocrinological effects) Either benefit or harm 7. Quality of life or functioning (overall and disease-specific) 8. Psychological effects	N/A
Timing of outcome assessment	Not specified	N/A
Delivery setting	Any country	N/A
Study design	RCTs (including cluster RCTs), observational studies with consecutively enrolled populations	Case reports, case series, systematic reviewsb, narrative reviews, editorials, commentaries, letters, conference proceedings, government reports.
Language	English	N/A
Dates of publication	Before 2019 (UK NSC)	Full-text studies published prior to 2018 or 2014 for the specific interventions were not included in the NICE systematic review.

^aThe UK NSC has indicated that the rate of disease recurrence after successful initial treatment is an outcome of interest; however, this outcome is not of interest to the CTFPHC

^bThe reference list of relevant systematic reviews will be reviewed for relevant studies